Home|DSIJArticleDetail

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?
This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

This pharma company received USDA approval for a generic drug which clocked over Rs 90 crore in sales, do you own it?

The company is ranked among the world’s top 100 biopharmaceutical companies and among the world’s top 50 companies in the off-patent sector.

Bhavya Rathod Article rating: 4.4

Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?
Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Kiran Shroff Article rating: 4.3

This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!
Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

Heavy buying seen in these small-caps that hit fresh 52 week high on August 18!

On BSE, 265 stocks have hit their upper circuits whereas 131 stocks touched their lower circuits.  

Sayali Kotwal Article rating: 4.2

At 2.30 pm on Thursday, the markets were seen recovering from the day’s low as Asia- Pacific markets tumbled following the overnight cooling off of the most recent Wall Street rise.  

DSIJ MINDSHARE

Mkt Commentary20-Dec, 2024

Swing Trading22-Dec, 2024

IPO Analysis20-Dec, 2024

Mindshare20-Dec, 2024

IPO Analysis20-Dec, 2024

Knowledge

MF15-Nov, 2024

General15-Nov, 2024

MF14-Nov, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList